Pol. Merkur. Lek (Pol. Med. J.), 2019, XLVI/271: 032-035 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2019, XLVI/271: 032-035

Title: Autoimmunity in lichen planopilaris patients 

Authors: Kłosowicz A, Englert K, Pełka K, Pastuszczak M, Wojas-Pelc A.

More details


40,00 zł


Autoimmunity in lichen planopilaris patients

Kłosowicz A, Englert K, Pełka K, Pastuszczak M, Wojas-Pelc A.

Department of Dermatology, Jagiellonian University, Collegium Medicum, Cracow, Poland

Lichen planopilaris (LPP) is a rare, scarring form of alopecia with lymphocytic pattern. Due to the destruction of epithelial hair follicle stem cells in the bulge, it represents an irreversible condition. Antinuclear antibodies have been used for decades as diagnostic biomarkers of several rheumatological diseases.
The aim of study
was to determine the frequency of anti-nuclear antibodies positivity and subsequently analyze the presence of specific antibodies in LPP patients.
Material and methods
. 57 patients (aged 28-79, female 96%) were included in the study. Patients with LPP were treated in Department of Dermatology of University Hospital in Cracow, Poland and were identified on individual record review. Antinuclear antibodies were detected using indirect immunofluorescence on HEp-2 cells and immunoblot test.
. Antinuclear antibodies were detected in sera of 48 out of 57 LPP patients (84,2%). In 22 (46%) patients antinuclear antibodies specificity could be defined, anti-dsDNA and anti-Ro/anti-SSA being most common.
. Reports of LPP association with other autoimmune conditions suggest the evidence of an autoimmune etiology for this condition. Since antinuclear antibodies can be detected many years before disease onset, our study further emphasizes that dermatologists should screen patients with LPP for autoimmune disorders.

Key words: lichen planopilaris, frontal fibrosing alopecia, primary cicatrical alopecia, autoimmunity, antinuclear antibodies

Pol Med J, 2019; XLVI (271); 32–35